Unresolved questions regarding the promise of the TPEx regimen

Lancet Oncol. 2021 Jun;22(6):e227. doi: 10.1016/S1470-2045(21)00246-1.

Authors

Makoto Kosaka¹, Yoshitaka Honma², Hiroto Ishiki³

Affiliations

¹ Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
³ Department of Palliative Medicine, National Cancer Center Hospital, Tokyo 104-0045, Japan. Electronic address: ishiki-tky@umin.ac.jp.

PMID: 34087137
DOI: 10.1016/S1470-2045(21)00246-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Cetuximab
Cisplatin*
Docetaxel
Fluorouracil
Humans
Platinum*

Substances

Docetaxel
Platinum
Cetuximab
Cisplatin
Fluorouracil